These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39257809)

  • 1. Neuroendocrine Prostate Cancer Drivers SOX2 and BRN2 Confer Differential Responses to Imipridones ONC201, ONC206, and ONC212 in Prostate Cancer Cell Lines.
    Purcell C; Srinivasan PR; Pinho-Schwermann M; MacDonald WJ; Ding E; El-Deiry WS
    bioRxiv; 2024 Aug; ():. PubMed ID: 39257809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine differentiation (ND) in sensitivity of neuroendocrine tumor (NET) cells to ONC201/TIC10 cancer therapeutic.
    Ding E; Pinho-Schwermann M; Zhang S; Purcell C; El-Deiry WS
    bioRxiv; 2024 Aug; ():. PubMed ID: 39257758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine pre-treatment impairs the anti-cancer effect of integrated stress response- and TRAIL pathway-inducing ONC201, ONC206 and ONC212 imipridones in pancreatic, colorectal cancer but not DMG cells.
    Zhang Y; Tapinos N; Lulla R; El-Deiry WS
    Am J Cancer Res; 2024; 14(5):2453-2464. PubMed ID: 38859853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent preclinical sensitivity to imipridone-based combination therapies in oncohistone H3K27M-mutant diffuse intrinsic pontine glioma is associated with induction of the integrated stress response, TRAIL death receptor DR5, reduced ClpX and apoptosis.
    Borsuk R; Zhou L; Chang WI; Zhang Y; Sharma A; Prabhu VV; Tapinos N; Lulla RR; El-Deiry WS
    Am J Cancer Res; 2021; 11(9):4607-4623. PubMed ID: 34659909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors.
    Chang WI; Honeyman JN; Zhang J; Lin C; Sharma A; Zhou L; Oliveira J; Tapinos N; Lulla RR; Prabhu VV; El-Deiry WS
    Am J Cancer Res; 2023; 13(12):6241-6255. PubMed ID: 38187038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas.
    Przystal JM; Cianciolo Cosentino C; Yadavilli S; Zhang J; Laternser S; Bonner ER; Prasad R; Dawood AA; Lobeto N; Chin Chong W; Biery MC; Myers C; Olson JM; Panditharatna E; Kritzer B; Mourabit S; Vitanza NA; Filbin MG; de Iuliis GN; Dun MD; Koschmann C; Cain JE; Grotzer MA; Waszak SM; Mueller S; Nazarian J
    Neuro Oncol; 2022 Sep; 24(9):1438-1451. PubMed ID: 35157764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ONC206 has anti-tumorigenic effects in human ovarian cancer cells and in a transgenic mouse model of high-grade serous ovarian cancer.
    Tucker K; Yin Y; Staley SA; Zhao Z; Fang Z; Fan Y; Zhang X; Suo H; Sun W; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
    Am J Cancer Res; 2022; 12(2):521-536. PubMed ID: 35261784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.
    Lev A; Lulla AR; Wagner J; Ralff MD; Kiehl JB; Zhou Y; Benes CH; Prabhu VV; Oster W; Astsaturov I; Dicker DT; El-Deiry WS
    Oncotarget; 2017 Oct; 8(47):81776-81793. PubMed ID: 29137221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
    Bonner ER; Waszak SM; Grotzer MA; Mueller S; Nazarian J
    Neuro Oncol; 2021 Apr; 23(4):542-556. PubMed ID: 33336683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Antiproliferative Activity of Novel Imipridone-Ferrocene Hybrids with Triazole and Alkyne Linkers.
    Czuczi T; Murányi J; Bárány P; Móra I; Borbély A; Csala M; Csámpai A
    Pharmaceuticals (Basel); 2022 Apr; 15(4):. PubMed ID: 35455465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Therapeutic Mechanism of Imipridones ONC201/ONC206 in MYCN-Amplified Neuroblastoma Cells
    El-Soussi S; Hanna R; Semaan H; Khater AR; Abdallah J; Abou-Kheir W; Abou-Antoun T
    Front Pediatr; 2021; 9():693145. PubMed ID: 34422720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
    Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
    Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
    Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
    Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevating SOX2 in prostate tumor cells upregulates expression of neuroendocrine genes, but does not reduce the inhibitory effects of enzalutamide.
    Metz EP; Wilder PJ; Dong J; Datta K; Rizzino A
    J Cell Physiol; 2020 Apr; 235(4):3731-3740. PubMed ID: 31587305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly potent dopamine receptor D2 antagonist ONC206 demonstrates anti-tumorigenic activity in endometrial cancer.
    Staley A; Tucker K; Yin Y; Zhang X; Fan Y; Zhang Y; Fang Z; Sun W; Suo H; Zhao X; Zhao Z; Prabhu VV; Allen JE; Zhou C; Bae-Jump VL
    Am J Cancer Res; 2021; 11(11):5374-5387. PubMed ID: 34873466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GABA production induced by imipridones is a targetable and imageable metabolic alteration in diffuse midline gliomas.
    Batsios G; Udutha S; Taglang C; Gillespie AM; Lau B; Ji S; Phoenix T; Mueller S; Venneti S; Koschmann C; Viswanath P
    bioRxiv; 2024 Jun; ():. PubMed ID: 38915617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.
    Farmaki E; Nath A; Emond R; Karimi KL; Grolmusz VK; Cosgrove PA; Bild AH
    Elife; 2023 Sep; 12():. PubMed ID: 37772709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.